Treatment of peritoneal surface malignancies makes physicians face demanding and new-fangled
problems, as there are many uncertain aspects considering the outcomes of affected
patients’ prognoses. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) are associated with favorable long-term outcomes in carefully
selected patients with peritoneal metastases (PM). We aim to summarize the current
results about the initial malignancies and their peritoneal spreads. The current literature
has been scrutinized, and studies between 2016 and 2022 were included wherein long-term,
progression-free (PFS), and overall survival (OS) data were considered relevant information.
Medline, Embase, and Google Scholar have been the main sources. Hereby, we cover all
the primer malignancies: gastric, ovarian, and colorectal cancers with peritoneal
metastases (PM), malignant peritoneal mesothelioma, and pseudomyxoma peritonei. Examining
the advances in the current peer-reviewed literature about the indications of cytoreductive
surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), target groups,
risk factors, and other influencing elements, we intend to provide a complex state-of-the-art
report, establishing the relevant aspects of that emerging treatment method.
